Skip to main content
. Author manuscript; available in PMC: 2019 Mar 6.
Published in final edited form as: Surgery. 2017 Feb 21;162(1):104–111. doi: 10.1016/j.surg.2016.12.029

Table 2.

AJCC 7th edition staging System for pancreatic adenocarcinoma and observed cause-specific survival in patients with pancreatic adenocarcinoma, SEER* Research Database 2004–2012.

Stage AJCC 7th Edition TNM Staging
System		 Number of
Patients		 Median
Survival
(months)		 5 Year Survival
(%)
IA T1 N0 M0 646 26 34.6%
IB T2 N0 M0 2,109 9 14.2%
IIA T3 N0 M0 5,345 11 10.4%
IIB T1-T3 N1 M0 7,335 14 10.4%
 T1N1M0 236 19 19.0%
 T2N1M0 951 13 11.6%
 T3N1M0 6,143 14 10.4%
III T4 N0-N1 M0 4,693 9 2.7%
IV T1-T4 N0-N1 M1 25,019 3 0.8%
*

SEER, Surveillance, Epidemiology, and End Results Program

†

TMN, Tumor Node Metastasis. T1: a tumor ≤ 2 cm is confined to the pancreas, T2: a tumor confined to the pancreas and > 2 cm, T3: a tumor that has grown outside of the pancreas but not into vessels, T4: a tumor with vascular involvement.